The following is a summary of the Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript:
Financial Performance:
Lisata reported Q1 2024 operating expenses of $6.6 million, a decrease of 3.6% compared to 2023.
Research and Development expenses saw a negligible increase of $62,000, or 2%.
General and Administrative expenses fell down by 8.3% due to reduced staffing costs and legal consulting fees.
Lisata recorded a net loss of $5.4 million for Q1 2024, down by 13% from 2023.
Lisata held cash equivalents of $43.3 million as of March 31 believed to fund operations till early 2026.
Business Progress:
Lisata's lead product certepetide is undergoing development for treating solid tumor cancers.
The company is focused on key milestones from their ongoing clinical trials.
They plan to maintain certepetide's conditional approval through required Phase 3 studies.
Its development strategy involves a rapid certepetide registration for treating metastatic pancreatic ductal adenocarcinoma.
Lisata terminated its trials on head and neck and esophageal cohorts, now focusing on the cholangiocarcinoma arm of the BOLSTER trial.
More details: Lisata Therapeutics IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.